Science 37 Holdings, Inc (SNCE): Price and Financial Metrics
SNCE Price/Volume Stats
Current price | $5.75 | 52-week high | $12.96 |
Prev. close | $5.73 | 52-week low | $3.73 |
Day low | $5.73 | Volume | 49,100 |
Day high | $5.75 | Avg. volume | 43,227 |
50-day MA | $5.60 | Dividend yield | N/A |
200-day MA | $5.84 | Market Cap | 34.33M |
SNCE Stock Price Chart Interactive Chart >
SNCE Stock Summary
- For SNCE, its debt to operating expenses ratio is greater than that reported by just 3.57% of US equities we're observing.
- With a year-over-year growth in debt of -94.62%, SCIENCE 37 HOLDINGS INC's debt growth rate surpasses merely 0.99% of about US stocks.
- In terms of volatility of its share price, SNCE is more volatile than 99.73% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to SCIENCE 37 HOLDINGS INC, a group of peers worth examining would be BSM, OLB, RNGR, METC, and POWW.
- To check out SCIENCE 37 HOLDINGS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001819113.
SNCE Valuation Summary
- SNCE's price/sales ratio is 0.5; this is 77.27% lower than that of the median Healthcare stock.
- SNCE's price/sales ratio has moved down 6.2 over the prior 38 months.
Below are key valuation metrics over time for SNCE.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
SNCE | 2023-12-29 | 0.5 | 0.6 | -0.3 | 0.2 |
SNCE | 2023-12-28 | 0.5 | 0.6 | -0.3 | 0.2 |
SNCE | 2023-12-27 | 0.5 | 0.6 | -0.3 | 0.2 |
SNCE | 2023-12-26 | 0.6 | 0.7 | -0.3 | 0.2 |
SNCE | 2023-12-22 | 0.4 | 0.5 | -0.2 | 0.2 |
SNCE | 2023-12-21 | 0.4 | 0.5 | -0.2 | 0.3 |
Science 37 Holdings, Inc (SNCE) Company Bio
Science 37 Holdings, Inc. engages in enabling universal access for clinical research to accelerate the development of treatments for patients and providers. The company develops decentralized clinical trials (DCT) technology platform that enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, as well as sponsors?to power workflows, centralize evidence generation, and harmonize data. It also offers Science 37 Metasite that provides networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating decentralized clinical trials. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, medical device, and biotech companies. The company was formerly known as Science 37, Inc. and changed its name to Science 37 Holdings, Inc. in October 2021. Science 37 Holdings, Inc. was founded in 2014 and is based in Culver City, California.
Latest SNCE News From Around the Web
Below are the latest news stories about SCIENCE 37 HOLDINGS INC that investors may wish to consider to help them evaluate SNCE as an investment opportunity.
Science 37 Receives Top Honors in Everest PEAK Matrix®Science 37 emerges as the only clinical trial site to be recognized as a Leader in Decentralized Clinical TrialsRESEARCH TRIANGLE PARK, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ today announced that it has been named a Leader in the Decentralized Clinical Trials (DCT) PEAK Matrix® Assessment by the Everest Group, for the third consecutive year. The only clinical trial site to be named as a Leader in the PEAK |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! |
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. Amended and Restated 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2023. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Commit |
Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (“Science 37” or the “Company”), the clinical research industry-leading Metasite™, announced today that it will effect a 1-for-20 reverse stock split (“Reverse Stock Split”) of its outstanding common stock, par value $0.0001 per share (“Common Stock”), that will become effective on December 8, 2023, at 12:01 a.m., Eastern Time. Science 37’s Common Stock will continue to trade on The Nasdaq Ca |
Science 37 Holdings, Inc. (NASDAQ:SNCE) Q3 2023 Earnings Call TranscriptScience 37 Holdings, Inc. (NASDAQ:SNCE) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Greetings and welcome to the Science 37 Third Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steve Halper from LifeSci Advisors. Thank you, Steve. You may […] |
SNCE Price Returns
1-mo | 0.17% |
3-mo | 7.68% |
6-mo | -28.13% |
1-year | 11.61% |
3-year | -97.15% |
5-year | N/A |
YTD | 7.68% |
2023 | -35.69% |
2022 | -96.67% |
2021 | 16.87% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...